The failure of the bardoxolone methyl clinical study suggests the importance of animal experiments to identify precise modes of action of candidate drugs before applying them to a clinical setting; however, there still remains a possibility that NRF2 activators can be beneficial in managing CKD. Here, NFE2L2 is linked to chronic kidney disease.